Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NFκB activation

Pei Yen Yeh, Shuang En Chuang, Kun Huei Yeh, Ying Chyi Song, Chee Kwee Ea, Ann Lii Cheng

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

In this study, we showed that suppression of the MEK-ERK transduction pathway by a selective inhibitor, 2′-amino-3′-methoxyflavone (PD98059), increased drug resistance of SiHa cells to cisplatin, but not to another common anticancer drug, doxorubicin. The downstream mechanism of this discrepant cellular response was investigated. Both cisplatin and doxorubicin activated nuclear ERK2 and nuclear transcription factor κB (NFκB) of SiHa cells. However, suppression of the MEK-ERK2 pathway by PD98059 resulted in a further enhancement of cisplatin-induced NFκB activation, while no further regulation of NFκB was noted in doxorubicin-treated cells. The activation of NFκB by cisplatin or doxorubicin was not due to the degradation of cytoplasmic IκBα, as demonstrated by western blotting. Transfection of a dominant negative IκBα resulted in a markedly diminished PD98059-induced cisplatin resistance in SiHa cells. Our results suggest that the MEK-ERK signaling pathway plays a role in the chemosensitivity of SiHa cells, and suppression of this pathway increases cisplatin resistance partly via an increase of NFκB activation. The mechanism responsible for the discrepant effect of PD98059 on NFκB activation and hence the chemosensitivity of SiHa cells towards cisplatin and doxorubicin remains to be investigated.

Original languageEnglish (US)
Pages (from-to)1423-1430
Number of pages8
JournalBiochemical Pharmacology
Volume63
Issue number8
DOIs
StatePublished - Apr 15 2002

Fingerprint

MAP Kinase Signaling System
Mitogen-Activated Protein Kinase Kinases
Cisplatin
Transcription Factors
Chemical activation
Cells
Doxorubicin
Carcinoma
Pharmaceutical Preparations
Drug Resistance
Transfection
Western Blotting
Degradation
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one

Keywords

  • Cervical cancer
  • Drug resistance
  • ERK
  • NFκB
  • PD98059

ASJC Scopus subject areas

  • Biochemistry
  • Pharmacology

Cite this

Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NFκB activation. / Yeh, Pei Yen; Chuang, Shuang En; Yeh, Kun Huei; Song, Ying Chyi; Ea, Chee Kwee; Cheng, Ann Lii.

In: Biochemical Pharmacology, Vol. 63, No. 8, 15.04.2002, p. 1423-1430.

Research output: Contribution to journalArticle

@article{63cfeedc38fc408485a933224048f49c,
title = "Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NFκB activation",
abstract = "In this study, we showed that suppression of the MEK-ERK transduction pathway by a selective inhibitor, 2′-amino-3′-methoxyflavone (PD98059), increased drug resistance of SiHa cells to cisplatin, but not to another common anticancer drug, doxorubicin. The downstream mechanism of this discrepant cellular response was investigated. Both cisplatin and doxorubicin activated nuclear ERK2 and nuclear transcription factor κB (NFκB) of SiHa cells. However, suppression of the MEK-ERK2 pathway by PD98059 resulted in a further enhancement of cisplatin-induced NFκB activation, while no further regulation of NFκB was noted in doxorubicin-treated cells. The activation of NFκB by cisplatin or doxorubicin was not due to the degradation of cytoplasmic IκBα, as demonstrated by western blotting. Transfection of a dominant negative IκBα resulted in a markedly diminished PD98059-induced cisplatin resistance in SiHa cells. Our results suggest that the MEK-ERK signaling pathway plays a role in the chemosensitivity of SiHa cells, and suppression of this pathway increases cisplatin resistance partly via an increase of NFκB activation. The mechanism responsible for the discrepant effect of PD98059 on NFκB activation and hence the chemosensitivity of SiHa cells towards cisplatin and doxorubicin remains to be investigated.",
keywords = "Cervical cancer, Drug resistance, ERK, NFκB, PD98059",
author = "Yeh, {Pei Yen} and Chuang, {Shuang En} and Yeh, {Kun Huei} and Song, {Ying Chyi} and Ea, {Chee Kwee} and Cheng, {Ann Lii}",
year = "2002",
month = "4",
day = "15",
doi = "10.1016/S0006-2952(02)00908-5",
language = "English (US)",
volume = "63",
pages = "1423--1430",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NFκB activation

AU - Yeh, Pei Yen

AU - Chuang, Shuang En

AU - Yeh, Kun Huei

AU - Song, Ying Chyi

AU - Ea, Chee Kwee

AU - Cheng, Ann Lii

PY - 2002/4/15

Y1 - 2002/4/15

N2 - In this study, we showed that suppression of the MEK-ERK transduction pathway by a selective inhibitor, 2′-amino-3′-methoxyflavone (PD98059), increased drug resistance of SiHa cells to cisplatin, but not to another common anticancer drug, doxorubicin. The downstream mechanism of this discrepant cellular response was investigated. Both cisplatin and doxorubicin activated nuclear ERK2 and nuclear transcription factor κB (NFκB) of SiHa cells. However, suppression of the MEK-ERK2 pathway by PD98059 resulted in a further enhancement of cisplatin-induced NFκB activation, while no further regulation of NFκB was noted in doxorubicin-treated cells. The activation of NFκB by cisplatin or doxorubicin was not due to the degradation of cytoplasmic IκBα, as demonstrated by western blotting. Transfection of a dominant negative IκBα resulted in a markedly diminished PD98059-induced cisplatin resistance in SiHa cells. Our results suggest that the MEK-ERK signaling pathway plays a role in the chemosensitivity of SiHa cells, and suppression of this pathway increases cisplatin resistance partly via an increase of NFκB activation. The mechanism responsible for the discrepant effect of PD98059 on NFκB activation and hence the chemosensitivity of SiHa cells towards cisplatin and doxorubicin remains to be investigated.

AB - In this study, we showed that suppression of the MEK-ERK transduction pathway by a selective inhibitor, 2′-amino-3′-methoxyflavone (PD98059), increased drug resistance of SiHa cells to cisplatin, but not to another common anticancer drug, doxorubicin. The downstream mechanism of this discrepant cellular response was investigated. Both cisplatin and doxorubicin activated nuclear ERK2 and nuclear transcription factor κB (NFκB) of SiHa cells. However, suppression of the MEK-ERK2 pathway by PD98059 resulted in a further enhancement of cisplatin-induced NFκB activation, while no further regulation of NFκB was noted in doxorubicin-treated cells. The activation of NFκB by cisplatin or doxorubicin was not due to the degradation of cytoplasmic IκBα, as demonstrated by western blotting. Transfection of a dominant negative IκBα resulted in a markedly diminished PD98059-induced cisplatin resistance in SiHa cells. Our results suggest that the MEK-ERK signaling pathway plays a role in the chemosensitivity of SiHa cells, and suppression of this pathway increases cisplatin resistance partly via an increase of NFκB activation. The mechanism responsible for the discrepant effect of PD98059 on NFκB activation and hence the chemosensitivity of SiHa cells towards cisplatin and doxorubicin remains to be investigated.

KW - Cervical cancer

KW - Drug resistance

KW - ERK

KW - NFκB

KW - PD98059

UR - http://www.scopus.com/inward/record.url?scp=0037091048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037091048&partnerID=8YFLogxK

U2 - 10.1016/S0006-2952(02)00908-5

DO - 10.1016/S0006-2952(02)00908-5

M3 - Article

C2 - 11996883

AN - SCOPUS:0037091048

VL - 63

SP - 1423

EP - 1430

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 8

ER -